Skip to main content

Table 10 Percent alleviative effects of DSL-EA and DIL-EA extracts in benzene induced leukemia

From: Preclinical anticancer studies on the ethyl acetate leaf extracts of Datura stramonium and Datura inoxia

Evaluation parameters

Study Groups

Disease control

Positive control

DSL-LD (P)

DSL-HD (P)

DIL LD (P)

DIL HD (P)

DSL HD (T)

DIL HD (T)

Percent alleviative effect

Haematalogical parameters

 RBCs (×106)/μl

4.33 ± 0.065

41.80 ± 2.20a

32.90 ± 1.65c

38.71 ± 1.92ab

35.64 ± 0.85bc

39.66 ± 1.51ab

23.79 ± 1.62d

32.74 ± 1.88c

 WBCs (×103) /μl

7.78 ± 0.012

50.53 ± 0.87b

53.54 ± 0.33a

52.14 ± %0.49a

50.39 ± 0.35b

48.46 ± 0.15c

45.67 ± 0.57d

45.28 ± 0.46d

 Platelets (×103)/μl

344 ± 3.19

44.08 ± 0.79e

56.42 ± 0.58b

61.81 ± 0.75a

52.37 ± 0.89c

58.15 ± 0.76b

49.76 ± 0.58d

45.25 ± 0.86e

Endogenous antioxidant enzymes

 CAT (U/min)

0.5 ± 0.04

342.67 ± 8.33b

84.67 ± 15.53d

100 ± 1.20d

274 ± 12.49c

285.3 ± 27.15c

315.3 ± 17.47bc

410 ± 30.27a

 POD (U/min)

1 ± 0.04

209 ± 6.56b

70.33 ± 2.52e

122 ± 1.73d

63.33 ± 4.16e

317.67 ± 3.21a

183.67 ± 9.07c

301 ± 10.15a

 SOD (U/mg protein)

0.96 ± 0.05

261.81 ± 3.66a

154.17 ± 2.08e

198.96 ± 4.17c

190.63 ± 2.08cd

232.29 ± 3.76b

176.7 ± 10.43d

191.6 ± 10.26cd

 GST (nM/min/ml)

81.01 ± 0.44

191 ± 1.81b

33.72 ± 0.78e

99.22 ± 0.87c

34.43 ± 1.28e

266.29 ± 1.98a

67.07 ± 0.78d

101.08 ± 1.91c

Biochemical parameters

 ALT (U/L)

93.20 ± 2.64

50.67 ± 2.01b

50.83 ± 2.45b

54.36 ± 1.92ab

52.47 ± 1.78ab

56.96 ± 2.43a

58.13 ± 2.10a

57.46 ± 1.70a

 AST (U/L)

67.80 ± 2.05

59.73 ± 0.94bc

65.23 ± 1.50a

61.91 ± 1.27ab

54.72 ± 1.89de

58.58 ± 1.39bcd

56.96 ± 1.01cde

53.79 ± 1.69e

 ALP (U/L)

356 ± 5.69

60.69 ± 1.01bcd

58.38 ± 0.92de

61.14 ± 1.14abc

57.28 ± 0.81e

59.43 ± 0.35cde

62.15 ± 1.01ab

63.38 ± 1.13a

 Urea (mg/dl)

72.2 ± 2.76

62.59 ± 1.41a

51.01 ± 1.37c

57.02 ± 2.44ab

50.15 ± 1.18c

52.29 ± 1.71bc

61.52 ± 2.84a

59.65 ± 2.60a

 Creatinine (mg/dl)

2.89 ± 0.45

61.01 ± 5.04a

60.21 ± 3.34a

61.82 ± 4.19a

60.32 ± 3.89a

62.40 ± 2.78a

61.25 ± 3.51a

61.94 ± 2.50a

 Bilirubin (mg/ml)

7.56 ± 0.97

65.21 ± 2.82a

58.38 ± 1.23a

63.10 ± 8.54a

59.79 ± 4.37a

60.76 ± 3.44a

68.17 ± 1.07a

68.08 ± 5.16a

 Total proteins (g/dl)

2.14 ± 0.11

214.02 ± 18.19a

185.51 ± 23.36a

224.45 ± 27.63a

213.55 ± 29.55a

210.28 ± 23.22a

186.29 ± 17.50a

195.02 ± 19.61a

Lipid peroxidation assay

 TBARs (nM/min/mg protein)

133.7 ± 2.61

35.74 ± 0.82a

15.08 ± 1.65d

24.27 ± 1.11c

15.12 ± 1.74d

21.39 ± 1.22c

37.41 ± 0.89a

31.01 ± 1.32b

  1. Results of disease control are expressed as mean ± SD (n = 6, where n = number of rats analysed in each group). Alleviative effects of remaining groups are expressed as percent increase or decrease (bold) of tested parameters in comparison to the disease control group. Groups are compared statistically to the positive control group and superscripts (a-e) in individual rows specifying significance at p < 0.05